Elektrofi, Takeda partner to advance plasma protein therapeutics

By The Science Advisory Board staff writers

September 21, 2020 -- Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.

Under the evaluation agreement, Takeda will evaluate Elektrofi's microparticle-based formulation technology, Elektroject. Elektroject uses proprietary technology to generate highly concentrated, small-volume injections of monoclonal antibodies, therapeutic proteins, and other biologics.

Takeda will investigate the storage stability and properties of microparticles created by Elektroject, as well as the stability and formulations with high concentrations of a target protein. Terms of the agreement were not disclosed.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?